Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Doxorubicin, Paclitaxel, Trastuzumab in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
HER2 positive early breast cancer (EBC) in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy, for locally advanced (including inflammatory) disease or tumours >2cm in diameter.